Press Releases
EndoBarrier Data to be Presented at 4th World Congress on Interventional Therapies for Type 2 Diabetes
BOSTON and SYDNEY — 4 April 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that EndoBarrier data will be presented at the 4th World Congress on Interventional Therapies for Type 2...
read moreNew Scientific Advisory Board Member to Advance Focus on Treatment of Chronic Kidney Disease
BOSTON and SYDNEY — 2 April 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the addition of a new member to its Scientific Advisory Board (SAB). The SAB is welcoming Allon Friedman,...
read moreGI Dynamics Announces Extension of the Maturity Date of US $5M Convertible Note with Crystal Amber
BOSTON and SYDNEY – 31 March 2019 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has reached an agreement with Crystal Amber Fund Limited (Crystal Amber) to extend the maturity...
read moreAssociation of British Clinical Diabetologists Releases Results of EndoBarrier Obstructive Sleep Apnea Study
BOSTON and SYDNEY — 29 March 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive results on one-year data from the Association of British Clinical Diabetologists (ABCD)...
read moreGI Dynamics Announces US $1M Convertible Note and Warrant Financing from Crystal Amber Fund Limited
BOSTON and SYDNEY — 18 March 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has agreed to the terms of a US $1,000,000 convertible note and warrant...
read moreUK National Health Service EndoBarrier Service Releases Final Data of One-Year Outcome
BOSTON and SYDNEY — 15 March 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive results on final data from the United Kingdom’s National Health Service (NHS) EndoBarrier...
read moreGI Dynamics Announces Institutional Review Board Approval for EndoBarrier Pivotal Trial
BOSTON and SYDNEY — 14 February 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has received Institutional Review Board (IRB) approval to conduct its pivotal trial of...
read moreGI Dynamics Appoints Vice President of Clinical and Regulatory Affairs
BOSTON and SYDNEY — 4 January 2019 — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the appointment of Stephen Linhares to the position of vice president of clinical and regulatory affairs....
read moreGI Dynamics Announces Extension of the Maturity Date of US $5M Convertible Note with Crystal Amber
BOSTON and SYDNEY – 2 January 2019 – GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has reached an agreement with Crystal Amber Fund Limited (Crystal Amber) to extend the maturity...
read moreGI Dynamics Appoints Chief Financial Officer and Company Secretary
BOSTON and SYDNEY — 11 December 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce the appointment of Charles Carter to the position of chief financial officer. Carter’s role with GI Dynamics will encompass finance, accounting and...
read more